Sara Tolaney

109PUBLICATIONS
591CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersInnate immunityEconomic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (109)

|Aug 24, 2026
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

|Jul 30, 2026
Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management.

|Jul 13, 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

|Jun 05, 2026
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

|May 15, 2026
Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.

|May 13, 2026
Single-Cell Transcriptomics Reveals Immune Landscape Dynamics in Metastatic Hormone Receptor-Positive Breast Cancer Treated with Abemaciclib and Endocrine Therapy.

Pageof 19

Frequent Collaborators

17 joint publications

Ann Partridge

17 joint publications

Paolo Tarantino

16 joint publications

Hope S Rugo

15 joint publications

Nabihah Tayob